DK4073098T5 - Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse - Google Patents
Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK4073098T5 DK4073098T5 DK20830444.4T DK20830444T DK4073098T5 DK 4073098 T5 DK4073098 T5 DK 4073098T5 DK 20830444 T DK20830444 T DK 20830444T DK 4073098 T5 DK4073098 T5 DK 4073098T5
- Authority
- DK
- Denmark
- Prior art keywords
- ultra
- methods
- long
- fusion proteins
- acting insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950803P | 2019-12-19 | 2019-12-19 | |
| US202062988441P | 2020-03-12 | 2020-03-12 | |
| PCT/US2020/063673 WO2021126584A1 (en) | 2019-12-19 | 2020-12-07 | Ultra-long acting insulin-fc fusion proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4073098T3 DK4073098T3 (da) | 2023-11-20 |
| DK4073098T5 true DK4073098T5 (da) | 2024-07-22 |
Family
ID=74104207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20830444.4T DK4073098T5 (da) | 2019-12-19 | 2020-12-07 | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11352407B2 (da) |
| EP (2) | EP4282473A3 (da) |
| JP (1) | JP7405486B2 (da) |
| KR (2) | KR102865175B1 (da) |
| CN (1) | CN114846025B (da) |
| AU (1) | AU2020407365B2 (da) |
| BR (1) | BR112022012071A2 (da) |
| CA (1) | CA3159486A1 (da) |
| DK (1) | DK4073098T5 (da) |
| FI (1) | FI4073098T3 (da) |
| HR (1) | HRP20231433T1 (da) |
| HU (1) | HUE064376T2 (da) |
| IL (1) | IL294051A (da) |
| LT (1) | LT4073098T (da) |
| SI (1) | SI4073098T1 (da) |
| WO (1) | WO2021126584A1 (da) |
| ZA (1) | ZA202206047B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210029210A (ko) | 2018-06-29 | 2021-03-15 | 악스톤 바이오사이언시스 코퍼레이션 | 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CN116096733A (zh) | 2020-04-10 | 2023-05-09 | 阿卡斯通生物科学公司 | Covid-19融合蛋白的抗原特异性免疫疗法和使用方法 |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| TWI871539B (zh) | 2021-11-15 | 2025-02-01 | 美商美國禮來大藥廠 | 可保存之調配物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030040601A1 (en) | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| CA2754408A1 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| AU2011282977A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| EP2780463A4 (en) | 2011-11-18 | 2015-07-01 | Merck Sharp & Dohme | FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
| DK2804623T3 (da) | 2012-01-12 | 2019-11-11 | Bioverativ Therapeutics Inc | Kimære faktor viii-polypeptider og anvendelser deraf |
| CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| TWI708782B (zh) | 2013-02-26 | 2020-11-01 | 南韓商韓美藥品股份有限公司 | 新穎胰島素類似物及其用途 |
| WO2014190040A1 (en) * | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| EP3194429A4 (en) | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| JP2018504911A (ja) | 2015-01-29 | 2018-02-22 | ネックスヴェット オーストラリア プロプライエタリー リミテッド | 治療及び診断剤 |
| US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
| WO2016177771A1 (en) | 2015-05-04 | 2016-11-10 | Apogenix Ag | Single-chain cd40-receptor agonist proteins |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー/エス | 極性の組換え延長部を有するインスリン |
| EP3356407B1 (en) * | 2015-10-02 | 2021-11-03 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| CN108699120B (zh) | 2015-11-16 | 2022-05-13 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
| RU2764197C1 (ru) | 2016-09-23 | 2022-01-14 | Ханми Фарм. Ко., Лтд. | Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение |
| WO2018073185A1 (en) | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
| EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| TW201835099A (zh) | 2017-03-07 | 2018-10-01 | 美國凱斯西方瑞瑟夫大學 | 藉由第四雙硫鍵穩定之單鏈胰島素類似物 |
| WO2018217976A1 (en) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| BR112020002871A2 (pt) | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| EP3781147A4 (en) | 2018-04-16 | 2022-04-20 | University of Utah Research Foundation | Glucose-responsive insulin |
| KR20210029210A (ko) | 2018-06-29 | 2021-03-15 | 악스톤 바이오사이언시스 코퍼레이션 | 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3114395A1 (en) | 2018-09-25 | 2020-04-02 | Absci, Llc | Protein purification methods |
| TW202028229A (zh) | 2018-10-05 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 包含胰島素肽及egf(a)肽之雙功能化合物 |
| EP3883957A4 (en) | 2018-11-19 | 2022-08-17 | Case Western Reserve University | SINGLE-CHAIN INSULIN ANALOGS WITH POLYALANINE C-DOMAIN SUBSEGMENTS |
| US20220235111A1 (en) | 2019-05-17 | 2022-07-28 | Case Western Reserve University | Variant Single-Chain Insulin Analogues |
| WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CA3254188A1 (en) | 2022-03-16 | 2025-03-04 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Human insulin analogue, and fusion protein thereof and medical use thereof |
-
2020
- 2020-12-07 FI FIEP20830444.4T patent/FI4073098T3/fi active
- 2020-12-07 EP EP23198760.3A patent/EP4282473A3/en active Pending
- 2020-12-07 US US17/114,395 patent/US11352407B2/en active Active
- 2020-12-07 LT LTEPPCT/US2020/063673T patent/LT4073098T/lt unknown
- 2020-12-07 SI SI202030309T patent/SI4073098T1/sl unknown
- 2020-12-07 JP JP2022536936A patent/JP7405486B2/ja active Active
- 2020-12-07 CA CA3159486A patent/CA3159486A1/en active Pending
- 2020-12-07 AU AU2020407365A patent/AU2020407365B2/en active Active
- 2020-12-07 WO PCT/US2020/063673 patent/WO2021126584A1/en not_active Ceased
- 2020-12-07 BR BR112022012071A patent/BR112022012071A2/pt unknown
- 2020-12-07 HR HRP20231433TT patent/HRP20231433T1/hr unknown
- 2020-12-07 EP EP20830444.4A patent/EP4073098B1/en active Active
- 2020-12-07 CN CN202080088372.8A patent/CN114846025B/zh active Active
- 2020-12-07 KR KR1020227022527A patent/KR102865175B1/ko active Active
- 2020-12-07 KR KR1020257031841A patent/KR20250142943A/ko active Pending
- 2020-12-07 IL IL294051A patent/IL294051A/en unknown
- 2020-12-07 HU HUE20830444A patent/HUE064376T2/hu unknown
- 2020-12-07 DK DK20830444.4T patent/DK4073098T5/da active
-
2021
- 2021-11-19 US US17/531,033 patent/US11555058B2/en active Active
-
2022
- 2022-05-31 ZA ZA2022/06047A patent/ZA202206047B/en unknown
-
2023
- 2023-01-10 US US18/152,595 patent/US12606605B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4073098A1 (en) | 2022-10-19 |
| DK4073098T3 (da) | 2023-11-20 |
| US12606605B2 (en) | 2026-04-21 |
| LT4073098T (lt) | 2023-12-11 |
| BR112022012071A2 (pt) | 2022-08-30 |
| JP7405486B2 (ja) | 2023-12-26 |
| HUE064376T2 (hu) | 2024-03-28 |
| ZA202206047B (en) | 2023-08-30 |
| KR102865175B1 (ko) | 2025-09-30 |
| US11555058B2 (en) | 2023-01-17 |
| AU2020407365B2 (en) | 2023-09-21 |
| CA3159486A1 (en) | 2021-06-24 |
| EP4282473A3 (en) | 2024-02-21 |
| US20210309709A1 (en) | 2021-10-07 |
| CN114846025A (zh) | 2022-08-02 |
| NZ788617A (en) | 2024-10-25 |
| FI4073098T3 (fi) | 2023-11-15 |
| HRP20231433T1 (hr) | 2024-03-29 |
| SI4073098T1 (sl) | 2023-12-29 |
| US20230250148A1 (en) | 2023-08-10 |
| US11352407B2 (en) | 2022-06-07 |
| AU2020407365A1 (en) | 2022-06-09 |
| CN114846025B (zh) | 2025-11-11 |
| KR20250142943A (ko) | 2025-09-30 |
| KR20220115975A (ko) | 2022-08-19 |
| EP4073098B1 (en) | 2023-09-27 |
| US20220064251A1 (en) | 2022-03-03 |
| IL294051A (en) | 2022-08-01 |
| JP2023507376A (ja) | 2023-02-22 |
| WO2021126584A1 (en) | 2021-06-24 |
| EP4282473A2 (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3892628T3 (da) | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| DK4232463T3 (da) | Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses | |
| IL288373A (en) | flt3l-fc fusion proteins and methods of use | |
| DK4073098T5 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| DK3565579T3 (da) | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf | |
| IL281783A (en) | Sirpα binding proteins and methods of use thereof | |
| IL281683A (en) | Dll3 binding proteins and methods of use | |
| DK3565828T3 (da) | Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf | |
| DK3618928T3 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3601358T5 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3761980T3 (da) | Aminosyreforbindelser og fremgangsmåder til anvendelse | |
| IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
| DK3660045T3 (da) | Polypeptid, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3966207T3 (da) | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3694529T3 (da) | Trispecifikke proteiner og anvendelsesfremgangsmåder | |
| DK3966206T3 (da) | Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf | |
| DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| IL275742A (en) | IL-22 FC fusion proteins and methods of use | |
| IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3743447T3 (da) | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3491025T3 (da) | Fcrn-antistoffer og anvendelsesmetoder heraf | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof |